Dr Fonseca, talking at the IV International Workshop on Myeloma Genetics, Pharmacogenomics & Novel Therapeutics, discusses the occurrence of hypomethylation in myeloma and genomic prognostic modules for the disease.

The workshop was supported by an unrestricted medical education grant from the following companies; Celgene, Bristol Myers Squibb, Johnson and Johnson, Takeda Millennium, Novartis Oncology, Cephalon and Onyx Pharmaceuticals.